F M Investments LLC Takes $2.10 Million Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

F M Investments LLC bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 73,163 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,096,000.

Other institutional investors also recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its stake in Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 316 shares in the last quarter. AlphaQuest LLC boosted its position in shares of Collegium Pharmaceutical by 3.0% in the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company’s stock worth $366,000 after purchasing an additional 374 shares in the last quarter. Foundry Partners LLC grew its stake in shares of Collegium Pharmaceutical by 2.4% in the 4th quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company’s stock worth $463,000 after buying an additional 381 shares during the last quarter. Gallacher Capital Management LLC increased its position in Collegium Pharmaceutical by 3.3% during the 4th quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company’s stock valued at $417,000 after buying an additional 470 shares in the last quarter. Finally, TD Private Client Wealth LLC increased its position in Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after buying an additional 483 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on COLL. Piper Sandler cut their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. Needham & Company LLC reissued a “buy” rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Finally, StockNews.com upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Friday. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $43.60.

Collegium Pharmaceutical Trading Up 6.6 %

Shares of Collegium Pharmaceutical stock opened at $26.30 on Friday. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The stock has a market capitalization of $845.07 million, a PE ratio of 11.34 and a beta of 0.76. Collegium Pharmaceutical, Inc. has a 1-year low of $23.23 and a 1-year high of $42.29. The company’s fifty day simple moving average is $29.14 and its 200-day simple moving average is $31.60.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. The company had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. As a group, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insider Activity

In other news, EVP Shirley R. Kuhlmann sold 26,067 shares of the firm’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $28.50, for a total transaction of $742,909.50. Following the sale, the executive vice president now directly owns 108,137 shares in the company, valued at $3,081,904.50. This trade represents a 19.42 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Colleen Tupper sold 10,445 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total transaction of $313,454.45. Following the transaction, the chief financial officer now owns 165,246 shares in the company, valued at approximately $4,959,032.46. This trade represents a 5.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 81,693 shares of company stock valued at $2,334,994 in the last ninety days. Corporate insiders own 3.98% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.